Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease
dc.contributor.author | Schofield, C | |
dc.contributor.author | Chaudhuri, KR | |
dc.contributor.author | Carroll, Camille | |
dc.contributor.author | Sharma, JC | |
dc.contributor.author | Pavese, N | |
dc.contributor.author | Evans, J | |
dc.contributor.author | Foltynie, T | |
dc.contributor.author | Reichmann, H | |
dc.contributor.author | Zurowska, L | |
dc.contributor.author | Soares-da-Silva, P | |
dc.contributor.author | Lees, A | |
dc.date.accessioned | 2022-05-25T09:15:47Z | |
dc.date.available | 2022-05-25T09:15:47Z | |
dc.date.issued | 2022-04 | |
dc.identifier.issn | 1758-2024 | |
dc.identifier.issn | 1758-2032 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/19263 | |
dc.description.abstract |
<jats:p> Aim: This subanalysis of the OPTIPARK study aimed to confirm the effectiveness and safety of opicapone in patients with Parkinson's disease and motor fluctuations in clinical practice specifically in the UK and to assess the impact of opicapone on treatment costs. Methods: Patients received opicapone added to levodopa for 6 months. Clinical outcomes were assessed at 3 and 6 months and treatment costs at 6 months. Results: Most patients' general condition improved at 3 months, with sustained improvements reported at 6 months. Opicapone improved motor and non-motor symptoms at both timepoints, was generally well tolerated and reduced total treatment costs by GBP 3719. Conclusion: Opicapone added to levodopa resulted in clinical improvements and reduced treatment costs across UK clinical practice. </jats:p> | |
dc.format.extent | 77-91 | |
dc.format.medium | Print-Electronic | |
dc.language | en | |
dc.language.iso | eng | |
dc.publisher | Future Medicine Ltd | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Parkinson's disease | |
dc.subject | cost-saving | |
dc.subject | health economics | |
dc.subject | levodopa | |
dc.subject | motor fluctuations | |
dc.subject | opicapone | |
dc.subject | Antiparkinson Agents | |
dc.subject | Catechol O-Methyltransferase Inhibitors | |
dc.subject | Costs and Cost Analysis | |
dc.subject | Double-Blind Method | |
dc.subject | Humans | |
dc.subject | Levodopa | |
dc.subject | Oxadiazoles | |
dc.subject | Parkinson Disease | |
dc.subject | United Kingdom | |
dc.title | Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease | |
dc.type | journal-article | |
dc.type | Journal Article | |
dc.type | Research Support, Non-U.S. Gov't | |
plymouth.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35313124 | |
plymouth.issue | 2 | |
plymouth.volume | 12 | |
plymouth.publication-status | Published | |
plymouth.journal | Neurodegenerative Disease Management | |
dc.identifier.doi | 10.2217/nmt-2021-0057 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/FoH - Applied Parkinson's Research | |
plymouth.organisational-group | /Plymouth/Research Groups/FoH - Community and Primary Care | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CCT&PS | |
plymouth.organisational-group | /Plymouth/Research Groups/Plymouth Institute of Health and Care Research (PIHR) | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
dc.publisher.place | England | |
dcterms.dateAccepted | 2022-02-17 | |
dc.rights.embargodate | 2022-5-26 | |
dc.identifier.eissn | 1758-2032 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.2217/nmt-2021-0057 | |
rioxxterms.licenseref.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
rioxxterms.type | Journal Article/Review |